• Aucun résultat trouvé

Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study

N/A
N/A
Protected

Academic year: 2021

Partager "Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study"

Copied!
21
0
0

Texte intégral

(1)

HAL Id: hal-01534249

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01534249

Submitted on 4 Jul 2017

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Gemcitabine as second-line chemotherapy after

Folfirinox failure in advanced pancreatic

adenocarcinoma: A retrospective study

Juliette Viaud, Clémence Brac, Pascal Artru, Estelle Le Pabic, Bérengère

Leconte, Anaïs Bodere, Marc Pracht, Samuel Le Sourd, Julien Edeline, Astrid

Lièvre

To cite this version:

Juliette Viaud, Clémence Brac, Pascal Artru, Estelle Le Pabic, Bérengère Leconte, et al.. Gem-citabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarci-noma: A retrospective study. Digestive and Liver Disease, WB Saunders, 2017, 49 (6), pp.692-696. �10.1016/j.dld.2017.02.007�. �hal-01534249�

(2)

ÿ 1ÿ

23456

7896

3ÿ

8 ÿ

35 



6

3ÿ

534 7

38ÿ

8

73ÿ

 



6

6

ÿ



86



3ÿ

6

ÿ

8853ÿ

853876

5ÿ

83 5856

48

ÿ

8ÿ

37

 357

6

3ÿ

7ÿ

ÿ









ÿ

!

"#

1

$

ÿ

%

&'()ÿ

*+

")

,

$

ÿ

-".)"

ÿ

/+

+

0

$

ÿ

1.





ÿ

2ÿ

-"3

)

4

$

ÿ

*&+

(56+

ÿ

2)7(



1

$

ÿ

/("8

.ÿ

*7#6+



1

$

ÿ

9"+

)ÿ

-+

"):

,

$

ÿ

;"'

ÿ

2ÿ

;7+

#

,

$

ÿ







(ÿ

1#



(

<

ÿ

"(#ÿ

/.

+



#ÿ

2

6=+



>

ÿ

ÿ

?ÿABCÿDEFFEGHÿIEJKLMEÿNEGÿOPQPNLEGÿNEÿQRSTTPJELQÿULVEGWLXHÿDEFFEGHÿYJPFMEÿÿ ,ÿZ&["+OEFWÿNR\FM]Q]VLEÿ^_NLMPQEHÿAEFWJEÿ`aVEFEÿ^PJbaLGHÿc((.$ÿd+"()eÿÿ

fÿU_TPJWEOEFWÿNRg_TPW]VPGWJ]EFW_J]Q]VLEÿ ÿ7()775ÿ#5. =$ÿhi["ÿ"(ÿ9+'7j$ÿ2k7($ÿd+"()ÿ 4ÿ%hlÿc((.$ÿ;+=)ÿ#ÿ-:"+'")775ÿ%(m$ÿc((.$ÿd+"()nÿl(=+.&ÿc((.ÿ1$ÿ%o%ÿo(.+'ÿ1414$ÿ c((.$ÿd+"()ÿ

pÿU_TPJWEOEFWÿNR\FM]Q]VLEÿ^_NLMPQEHÿAEFWJEÿ`aVEFEÿ^PJbaLGHÿc((.$ÿd+"()nÿl(=+.&ÿc((.ÿ1$ÿd")&ÿ#ÿ '&#)($ÿc((.$ÿd+"()ÿ

qÿABCÿDEFFEGHÿIEJKLMEÿNEGÿOPQPNLEGÿNEÿQRSTTPJELQÿULVEGWLXHÿDEFFEGHÿYJPFMErÿCFLKEJGLW_ÿDEFFEGÿ?HÿYPMaQW_ÿNEÿ '&#)($ÿc((.$ÿd+"()ÿ

ÿ

1) +7()ÿs7+#ÿ%7( tÿ,0uuÿ ÿ

vwxxyz{w|}~|ÿ‚ƒ„wxÿ…ÿ†zƒx~}ÿ‡~ˆ‰xyÿ

IEJKLMEÿNEGÿOPQPNLEGÿNEÿQRPTTPJELQÿNLVEGWLXHÿABCÿŠ]FWMgPLQQ]aÿH‹ÿJaEÿBEFJLÿŒEÿaLQQ]aŽHÿfpffÿ c((.ÿ%#ÿ‘’ÿ

9"ÿtÿ". +#e=+“):”+((.e•+ÿ

ÿ

(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)

Références

Documents relatifs

Chaque matin, je prie pour que cette situation ne soit qu’un cauchemar, mais ce triste rêve est bien réel.. Je te hais à un point que tu ne peux imaginer, moi, la femme gentille

Ce type d’obtention s’opère uniquement quand le client et le détenteur de la ressource ont une relation hautement privilégiée et qu’aucune autre méthode ne peut

In 1999 the journal became officially associated with the European Society of Pathology and, with volume 454 in 2009, the journal metamorphosed in appearance (some like the

(c) The 3D contrast-enhanced gradient echo image with fat suppression acquired 2 min after contrast injection confirms a heterogeneous interface between the less enhancing

The aim of this cost-utility analysis was to assess the incre- mental cost-effectiveness ratio (ICER) of either the gemcita- bine or erlotinib strategy compared to observation, for

We studied CeO 2 -NP dissolution in the most common plant growth medium ‘‘Hoagland solution.’’ Here, we evaluated the individual effects of the constituents of this medium on

After progression under maintenance therapy by 5FU or FOLFIRI, reintroduction by triplet FOLFIRINOX or doublet of chemotherapy was performed in 28.1% of patients, i.e., 5 7.6%

In addition, more drastic biochemical response criteria (aminotransferases in the lower range of normal values and IgG&lt;12 g/L) have been reported to predict a